Saving on Gene Tests for Prostate Cancer Means Missing Key Risk Variants

Doctors want to find harmful gene changes in men who have prostate cancer that has already spread. These changes can open up new treatment options. They also help family members learn if they might face a higher chance of getting cancer too. But testing everyone gets expensive fast. So the big question is simple. Who really needs to be tested?

Researchers looked at two possible plans. Plan one was to test every man with advanced prostate cancer. Plan two was to test only men who had extra warning signs pointing to a risky gene change. They also looked at what happens when a regular doctor, not a genetic specialist, talks to patients about the test. Using numbers from the Netherlands, they added up the costs and counted how many harmful variants each plan would catch.

The results show a tough trade off. Testing only high risk men costs about three times less than testing everyone. That sounds great on paper. But there is a serious catch. Around forty one percent of important harmful gene changes would slip through the cracks. Those men and their families would never even know they were at risk. So fewer dollars spent today could mean missed chances to catch cancer early in someone’s brother, father, or son.

This study pushes a bigger debate to the surface. How much is a country willing to spend to find every single risky gene? Saving money feels smart. But missing nearly half of the warning signs in families across the nation is a heavy price. It leaves patients, doctors, and policymakers stuck weighing pennies against lives. The choice is not easy, and the answer may shape how cancer care works for years to come.